Purpose: To investigate the anatomic outcomes and influencing factors of ranibizumab in the treatment of retinopathy of prematurity (ROP).
Retinopathy of prematurity (ROP) is a proliferative disorder of the developing retina in premature infants, and it continues to be a major cause of childhood blindness worldwide. 1 The randomized trials Cryotherapy for ROP study and Early Treatment for ROP established cryotherapy for threshold ROP and laser photocoagulation for type 1 ROP, respectively. 2, 3 Although cryotherapy and laser photocoagulation can cure most cases of ROP, they are relatively destructive to the peripheral retina. The role of vascular endothelial growth factor (VEGF) in pathophysiology of ROP has been intensively studied, and various anti-VEGF drugs are used to treat ROP. The prospective, controlled, randomized, multicenter trial about anti-VEGF treatment for ROPdBevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematuritydshowed that bevacizumab was effective in treating ROP and was more effective than laser treatment in zone I ROP cases. 4 Since then, other scholars have published the results of anti-VEGF drugs for treating ROP. 5e7 Among them, bevacizumab has been the most reported thus far, and there have been only a few case reports or small case series of ranibizumab treatment. Bevacizumab is a humanized function-blocking monoclonal full-length murine antibody that binds to all VEGF isoforms. 8 Ranibizumab is a humanized recombinant G1 kappa isotype antibody fragment. It is structurally derived from the light chains of bevacizumab but has approximately 10 times greater affinity for VEGF. Bevacizumab is approximately 3 times larger than ranibizumab (149 vs. 48 kDa), and its higher molecular weight results in an intravitreal half-life that is 36% higher than that of ranibizumab. 9 Ranibizumab appeared transiently in systemic circulation and was rapidly cleared. Serum VEGF levels decrease after bilateral injection of 0.2 mg of ranibizumab, reaching a nadir at approximately 2 weeks and returning to normal levels 4 weeks after injection. 10, 11 Bevacizumab, by contrast, was cleared relatively slowly from systemic circulation. It was found to enter the systemic circulation 1 day after intravitreal injection of bevacizumab (IVB) and to remain detectable for 8 weeks in the patients with ROP who received 0.625 mg IVB. 12 We report our experience of the intravitreal injection of ranibizumab (IVR) in the treatment of ROP by collecting a large number of cases. We also discuss potential prognostic factors with regard to the outcomes after IVR.
Methods

Study Design
This was a retrospective study that was conducted in tertiary-level neonatal intensive care units (NICUs) and the referral ROP screening center in Xinhua Hospital, affiliated to Shanghai Jiao Tong University School of Medicine. Consecutive patients who were diagnosed with ROP and accepted IVR as primary treatment from January 2012 to August 2015 at Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine were included. Their complete medical records were reviewed, and patients who were followed up for less than 6 months were excluded. All of the infants with ROP who required treatment were hospitalized in the NICU. This study was conducted with Institutional Review Board approval and adhered to the tenets of the Declaration of Helsinki. The legal guardian of each patient signed a consent form before any examination or treatment.
Screening and Treatment
Infants were screened for ROP if they were born at gestational age (GA) <32 weeks and their birth weight (BW) was <2000 g or if they had an unstable clinical course, as determined by the infant's neonatologist according to Chinese guidelines. The first screening was at 4 to 6 weeks after birth or at 31 to 32 weeks postmenstrual age (PMA), whichever came first. The International Classification of Retinopathy of Prematurity 2005 was used. At the screening and follow-up, all cases had fundus photography by RetCam Imaging System (Clarity Medical System, Pleasanton, CA). In some patients, additional examinations were performed under anesthesia after IVR for intraocular pressure via an iCare tonometer (Icare Finland Oy, Vantaa, Finland) and the axial length via a B-scan (Quantel Medical, Clermont-Ferrand, France). The cycloplegic agent used was tropicamide phenylephrine eye drops (Santen Pharmaceutical Co., Ltd., Osaka, Japan). Treated infants were kept hospitalized for at least 2 weeks after IVR in the NICU, where the systemic conditions of the infants were evaluated before and after injection, including the oxygen saturation, complete blood count, renal and liver function tests, chest x-rays, and abdomen and head ultrasound examinations.
The indications for IVR as a primary treatment were patients who met the criteria for type 1 ROP used in the Early Treatment for Retinopathy of Prematurity study. 3 A 0.25 mg/0.025 ml dose of ranibizumab (half of the dose administered intravitreally in adults for ocular neovascular diseases) 4, 13, 14 was injected into each eye, using the following technique: topical anesthesia, sterile gloves, insertion of a lid speculum, instillation of topical povidone-iodine, injection of ranibizumab with a sterile 30-gauge 0.5-inch needle at 0.5 to 1 mm posterior to the limbus, removal of the needle with simultaneous compression using a sterile cotton tip, instillation of topical tobramycin, and removal of the speculum. If the other eye was to be treated, new equipment was used. After injection, the patients underwent binocular indirect ophthalmoscopy to assess the lens clarity, retinal breaks, and retinal artery or optic nerve perfusion. 6, 15 The patients were reexamined the next day and then every week to monitor the progression of the disease until full vascularization was noted or additional treatment was given. The IVR injection, laser treatment, lensectomy, and vitrectomy were all performed by the same experienced surgeon (P.Z.).
Classification of Patients
We classified all eyes into 2 groups according to their response to a single IVR: the positive response group and the negative/no response group (Fig 1) . Furthermore, the positive response group was classified into 2 subgroups: the regression without reactivation subgroup and the regression with reactivation subgroup. The positive response group was defined as follows: Ridge and venous dilation and arteriolar tortuosity of the posterior retinal vessels (plus disease) 16 regressed after IVR, and retinal vessels continued to develop into the peripheral area. The negative/no response group was defined as follows: ROP worsened after IVR and developed into Stage 4A, 4B, or 5, or plus disease and ridge did not show any change 1 week after IVR. The regression without reactivation subgroup was defined as plus disease, ridge regressed after IVR without reoccurrence, and flat retina was achieved at the last visit. 6 The regression with reactivation subgroup was defined as eyes with reoccurrence of plus disease or ridge during follow-up. Considering the economic burden and difficulty of obeying a prolonged follow-up schedule more than 6 months in most cases, we chose laser as a re-treatment for patients in the regression with reactivation subgroup.
Data Analysis
We performed statistical analysis with the program IBM SPSS 22 (SPSS Inc., Chicago, IL). KolmogoroveSmirnov tests were used to analyze the distribution of the samples, and chi-square and Fisher exact tests were performed to compare categoric data. The independent t test and KruskaleWallis test were used to compare the means. Logistic regression analyses were performed to assess the impact of various patient and treatment factors on the outcomes after IVR. The categoric dependent variable was the ROP regression. The predictor variables were GA, BW, PMA at injection, postnatal age (PNA) at injection, and initial ROP classification. A decision tree was constructed to predict the outcomes of IVR. A P value < 0.05 was considered significant.
Results
A total of 283 eyes of 146 patients were included. There were 97 male and 49 female patients. The ROP types and the mean GA of the patients are presented in Table 1 .
According to our classification scheme, there were a total of 266 eyes (94.0%) in the positive response group and 17 eyes (6.0%) in the negative/no response group (Fig 2) .
In the positive response group, 92 eyes (34.6%) were zone I ROP, 132 eyes (49.6%) were zone II ROP, and 42 eyes (15.8%) Figure 1 . Classification of the outcomes after ranibizumab injection. All eyes were classified into 2 groups: positive response and negative/no response. Furthermore, in the positive response group, we classified patients into 2 subgroups: the regression without reactivation subgroup and the regression with reactivation subgroup.
were aggressive posterior ROP (APROP). Of them, 139 eyes (48.6%) were in the regression without reactivation subgroup, and 127 eyes (44.9%) were in the regression with reactivation subgroup. There were significant differences among the BW, PMA, and PNA at IVR of the positive response group and the negative/no response group using the independent KruskaleWallis test, and there were significant differences between the mean BWs of the regression without reactivation subgroup and the regression with reactivation subgroup using the independent t test ( Table 2) .
The time between reactivation and the initial IVR was 16 to 108 days (2.3e15.4 weeks), with an average of 58.5AE18.6 days (8.3AE2.7 weeks). The reactivation rate was 46.9% in APROP, 57.8% in zone I, and 35.4% in zone II. All reactivation eyes received laser treatment. The plus disease and ridge regressed, and retina remained flat after laser treatment.
Eight eyes in the regression without reactivation subgroup still had a large avascular area in the zone II and zone III areas at 24 weeks after IVR. Abnormal vessel shunting also was observed in 2 of these eyes. These 8 eyes received additional laser treatment.
Of the 17 eyes that had negative/no response, 5 eyes were APROP, 11 eyes were zone 1 stage 3þ, and 1 eye was zone 2 stage 3þ ROP at screening. Two eyes progressed to stage 4A, 5 eyes progressed to stage 4B, 4 eyes progressed to stage 5, 4 eyes had marked posterior fibrosis, and 1 eye had no response after IVR (Table 3) . At the last visit, 278 eyes (98.2%) had attached retinas, and 5 eyes (1.8%) had retinal detachment.
Nonconditional logistic regression was used to identify the predictive factors of a positive response after IVR. The results indicated that BW and PNA were independent factors. In the positive response group, nonconditional logistic regression showed that the GA and ROP type were independent factors for reactivation (Table 4) .
On the basis of logistic regression, we also constructed a classification tree model using the Classification and Regression Trees (CRT) growing method to predict what types of patients have a high risk of reactivation. The dependent variable was reactivation, and the independent variables were GA and ROP type (Fig 3) . The tree model showed that for patients with GA 29.5 weeks, the possibility of experiencing reactivation after IVR injection was higher than for those with GA >29.5 weeks (61.6% vs. 29.6%). Moreover, for patients with GA 29.5 weeks, those who were diagnosed with zone II stage 2þ ROP had a lower possibility of experiencing reactivation than other patients (37.9% compared with 80%). The overall correct percentage of this predictive tree diagram is 71.4%. The falsenegative rate is 12%, and the false-positive rate is 46%.
The major ocular complications associated with IVR in our study included cataract in 2 eyes (0. 
Discussion
In this study, we found that IVR as primary treatment resulted in a positive response in 94% of ROP eyes. To our knowledge, this case series is the largest ever reported for ranibizumab use in ROP. In addition, it is the first time that a tree model was introduced to predict reactivation after IVR in patients with ROP. According to the tree model in our series, factors that determine the outcomes of ranibizumab monotherapy are GA and ROP types.
Compared with reports of bevacizumab use in ROP, such as the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity study and the report of Wu et al, 6 our reactivation rate was higher (Table 5) . 4, 17 Chen et al 17 reported that 151 eyes that received IVR had a reactivation rate of 33.1%, which is a similar value to ours. These differences in effect make sense given the differences in the drug half-life. Ranibizumab has a shorter half-life and smaller molecular weight. 18, 19 Wong et al 14 also demonstrated that ranibizumab treatment had a higher chance of reactivation when compared with infants treated with bevacizumab. The differences may be related to the different ROP types enrolled. In our study, there were high proportions of zone I ROP and APROP, and zone I ROP and APROP require more time to achieve full vascularization after IVR. Reactivation occurs at any time if there is an increase in VEGF levels. The fact that the reactivation rate in zone I ROP in our study (57.8%) was higher than that in zone II (35.4%) confirmed this finding.
Incomplete vascularization and vascular abnormalities were observed in our study. Approximately 3% of eyes (8 eyes) had incomplete vascularization without reactivation after IVR. A large avascular area was found in the peripheral retina. Within those eyes, abnormal vessel shunting and branching also were observed according to fundus photography. These results confirm that there may be serious and lasting ocular structural abnormalities in eyes with ROP treated with ranibizumab. These phenomena also were reported in patients treated with bevacizumab. Tahija et al 20 showed that in their series of 20 eyes, complete normal peripheral retinal vascularization was not achieved in half of the patients. Lepore et al 21 studied the fundus fluorescein angiography results of 23 eyes and found that all eyes treated with bevacizumab injection had abnormalities at the periphery (large avascular area, abnormal branching, shunting) or the posterior pole (hyperfluorescent lesion, absence of foveal avascular zone). These posterior and peripheral lesions were not observed in the majority of the lasered eyes. 21 Toy et al 15 named these abnormalities "vascular arrest" and "scalloped regression." Considering the potential risk of retinal holes or tears in the avascular retina, we performed laser treatment on these eyes. The long-lasting implications of these abnormalities for the visual function of the child need to be studied. Although most ROP eyes showed a positive response to IVR, 5.7% of eyes still progressed to stage 4 or 5 and required vitrectomies or laser treatment to reattach the retina. Retinopathy of prematurity deterioration after ranibizumab or bevacizumab treatment has been reported, 22e26 but has not been analyzed statistically. We found that the PMA and PNA in the negative/no response group were larger than those in the positive response group. These findings indicated to us that delayed IVR treatment may lead to a negative or no response. Retinopathy of prematurity is a biphasic disease: a vaso-obliterative phase and a vasoproliferative phase. 27, 28 In the vasoproliferative phase, relative hypoxia peripheral avascular retina stimulates secretion of VEGF. Unlike other ocular neovascular conditions such as exudative age-related macular degeneration, in which there is continual release of VEGF, there is a single burst of VEGF that promotes neovascularization in ROP. 29 The delayed IVR treatment given at a period when VEGF levels are decreasing may promote fibrosis driven by connective tissue growth factor. 30, 31 Traction from fibrosis may cause retinal breaks or detachments.
The minimum effective dose of IVR for infants with ROP remains undetermined. The dose we used in this study was half of the dose administered intravitreally in adults for ocular neovascular diseases. This dose is the same that has been used in many reported cases. However, it has been argued that this dose might be relatively high for infants with ROP, considering their vitreous volume and body weight compared with those of adults. 32 It is certain that IVB and IVR can enter systemic circulation after intravitreal injection in both animal models and humans.
33e35 A case series has been reported in which one third of the adult dose of IVB produced the regression of retinal neovascular changes. 36 The bilateral effects of unilateral injections of both IVB and IVR have been described for both adults and children. 14, 37 Future studies of the optimal dose and unilateral anti-VEGF treatment in certain infants with ROP should be performed.
Treatment with IVR is less time-consuming and risky than conventional laser treatment, and it allows further retinal vascularization, whereas laser treatment can lead to permanent destruction of the peripheral retina. Ranibizumab is considered safer for premature infants than bevacizumab, because the systemic VEGF suppression seems to last for less time than that with bevacizumab. 10, 34 Our study showed high proportions of APROP and zone I ROP. This result is mainly because Xin Hua Hospital is a tertiary referral center in Shanghai that receives patients with severe ROP from all over the country, and those presenting to our clinic may not be representative of all ROP babies in China.
Study Limitations
The limitations of this study are its retrospective nature and the lack of a concomitant control group. In addition, it was a single-center study limited to an Asian population. No systemic complications were observed or reported to us from the neonatologists; however, this finding does not mean that there were none or that none would occur but rather that we did not detect any. Many questions remain unanswered, such as the optimal dose and timing of ranibizumab injection for treating ROP, as well as the long-term efficacy and safety of IVR in premature infants. Further study is needed to answer these questions.
In conclusion, the outcomes of ranibizumab and the influencing factors for the treatment of ROP are better understood because this study includes a larger number of patients than previous reports, and these patients were followed up for a long period of time. Ranibizumab injection seemed to be effective in treating patients with ROP. A single injection of ranibizumab resulted in a positive Figure 3 . Classification tree model showed that for patients with gestational age (GA) 29.5 weeks, their possibility of reactivation after injection of ranibizumab (IVR) is higher than that of those with GA >29.5 weeks (61.6% vs. 29.6%). Moreover, for patients with GA 29.5 weeks, those who are diagnosed with zone II stage 2þ retinopathy of prematurity (ROP) have a lower possibility of reactivation than other patients (37.9% vs. 80%). response in 94% of patients with ROP. Our predictive tree model is helpful for ophthalmologists in evaluating the prognosis and to tell patients they have a higher risk of reactivation. Close monitoring is necessary after IVR, especially for those high-risk patients.
